FIA
LOGC

FNY Investment Advisers’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

FNY Investment Advisers’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-6,200
Closed -$56K – 969
2020
Q3 		$56K Buy
+6,200
New +$47K 0.02% 241

Other funds holding LOGC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FNY Investment Advisers's LOGC Position: Q4 2020 in Review

FNY Investment Advisers sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q4 2020, closing a stake of 6,200 shares — an estimated $56K sold.

FNY Investment Advisers first reported a position in LOGC in Q3 2020 and held it in 1 quarter. The position peaked at $56K in Q3 2020. 59 funds tracked by Wall St. Rank hold LOGC as of Q4 2020.

  • FNY Investment Advisers reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • FNY Investment Advisers sold 6,200 LogicBio Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $56K.
  • FNY Investment Advisers first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q3 2020 and held it in 1 quarter.
  • FNY Investment Advisers's LogicBio Therapeutics, Inc. Common Stock position peaked at $56K in Q3 2020.
  • 59 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q4 2020.

Based on FNY Investment Advisers's 13F filing for Q4 2020, filed 19 Jan 2021.